This is a two-part study evaluating the effectiveness of CRD-740 in patients with either
Heart Failure with Reduced Ejection Fraction (HFrEF) or Heart Failure with Preserved Ejection
Fraction (HFpEF) after 12 weeks of treatment. The primary objective in Part A is to assess
the effect of CRD-740 compared to placebo in plasma cGMP at Week 4. The primary objective in
Part B is to determine whether CRD-740 reduces NT-proBNP compared to placebo at Week 12.